Research Analysts’ Recent Ratings Updates for GALAPAGOS NV/S (GLPG)

GALAPAGOS NV/S (NASDAQ: GLPG) has recently received a number of price target changes and ratings updates:

  • 10/11/2019 – GALAPAGOS NV/S was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 10/3/2019 – GALAPAGOS NV/S was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 10/2/2019 – GALAPAGOS NV/S was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 9/26/2019 – GALAPAGOS NV/S was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Galapagos NV is a biotechnology company. The Company’s operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium. “
  • 9/17/2019 – GALAPAGOS NV/S was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 9/9/2019 – GALAPAGOS NV/S is now covered by analysts at Morgan Stanley. They set an “overweight” rating and a $200.00 price target on the stock.
  • 9/6/2019 – GALAPAGOS NV/S was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 8/29/2019 – GALAPAGOS NV/S was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $189.00 price target on the stock. According to Zacks, “Galapagos NV is a biotechnology company. The Company’s operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium. “
  • 8/15/2019 – GALAPAGOS NV/S was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Galapagos NV is a biotechnology company. The Company’s operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium. “

NASDAQ GLPG traded up $0.42 on Friday, reaching $157.91. The company’s stock had a trading volume of 12,594 shares, compared to its average volume of 108,419. GALAPAGOS NV/S has a twelve month low of $85.00 and a twelve month high of $191.63. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.40 and a current ratio of 6.40. The stock has a market cap of $8.63 billion, a PE ratio of -239.26 and a beta of 1.55. The firm’s 50 day moving average is $159.85 and its two-hundred day moving average is $140.24.

GALAPAGOS NV/S (NASDAQ:GLPG) last issued its quarterly earnings results on Thursday, July 25th. The biotechnology company reported ($0.97) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.84) by ($0.13). GALAPAGOS NV/S had a negative net margin of 19.95% and a negative return on equity of 5.45%. The business had revenue of $75.96 million during the quarter, compared to analyst estimates of $56.66 million. Equities research analysts anticipate that GALAPAGOS NV/S will post 5.17 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Tower Research Capital LLC TRC raised its holdings in GALAPAGOS NV/S by 170.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 249 shares of the biotechnology company’s stock worth $32,000 after buying an additional 157 shares during the period. Royal Bank of Canada raised its holdings in GALAPAGOS NV/S by 206.1% during the 2nd quarter. Royal Bank of Canada now owns 251 shares of the biotechnology company’s stock worth $32,000 after buying an additional 169 shares during the period. Ladenburg Thalmann Financial Services Inc. acquired a new stake in GALAPAGOS NV/S during the 2nd quarter worth about $59,000. Quantamental Technologies LLC acquired a new stake in GALAPAGOS NV/S during the 2nd quarter worth about $74,000. Finally, Pacer Advisors Inc. acquired a new stake in GALAPAGOS NV/S during the 3rd quarter worth about $204,000. 15.58% of the stock is owned by institutional investors.

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Read More: Why does the United States have a lingering trade deficit?

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.